Evaluating Emetine for Viral Outbreaks (EVOLVE)

Description

The goal of this clinical trial (phase 2/phase 3) is to evaluate the efficacy and safety of emetine administered orally for symptomatic Covid-19 patients in patients ages 30 years and above. Participants will be asked to: * Take Emetine 6mg orally for 10 consecutive days * Be monitored by healthcare staff or self-monitor for daily vital signs and symptoms * Undergo blood draws Researchers will compare the control group given placebo medicine to assess if emetine improved the symptoms of Covid-19.

Conditions

COVID-19

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this clinical trial (phase 2/phase 3) is to evaluate the efficacy and safety of emetine administered orally for symptomatic Covid-19 patients in patients ages 30 years and above. Participants will be asked to: * Take Emetine 6mg orally for 10 consecutive days * Be monitored by healthcare staff or self-monitor for daily vital signs and symptoms * Undergo blood draws Researchers will compare the control group given placebo medicine to assess if emetine improved the symptoms of Covid-19.

Emetine for Viral Outbreaks: Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate Oral Emetine Against Covid-19 (EVOLVE)

Evaluating Emetine for Viral Outbreaks (EVOLVE)

Condition
COVID-19
Intervention / Treatment

-

Contacts and Locations

Baltimore

Johns Hopkins University, Division of Infectious Diseases, Baltimore, Maryland, United States, 21231

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 30 years of age or older at time of randomization
  • * RT-PCR positive for SARS-CoV-2 infection within ≤ 10 days of the screening visit.
  • * In addition to confirmed RT-PCR, symptomatic Covid-19 patients with at least two or more symptoms within 7 days of the screening visit: Cough, shortness of breath, fever/chills, sore throat, nausea, vomiting, diarrhea, fatigue, body aches, headache
  • * Ability to give informed consent (administered in local language)
  • * Asymptomatic Covid-19 patients
  • * Pregnant or breastfeeding woman
  • * Current or recent use of the study drug
  • * Known allergy to study drug
  • * Current or planned participation in another interventional trial in next 10 days.
  • * Critical Covid-19 patients (ARDS) at the time of screening.
  • * Patients needing intubation, mechanical ventilation, or ICU care at screening
  • * Patients with prior cardiac disease including cardiac dysrhythmias, heart failure, ischemic heart disease or cardiomyopathies.

Ages Eligible for Study

30 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Johns Hopkins University,

Kunchok Dorjee, MBBS, PhD, MPH, PRINCIPAL_INVESTIGATOR, Johns Hopkins School of Medicine

Study Record Dates

2026-09-14